Table 2.
Test | Substance | Subject | Prebiotic effect | Reference | ||
In vitro | DP 10–70 | Single microculture | Enhanced all Lactobacillus and Bifidobacterium strains examined | Al-Ghazzewi et al., 2007 | ||
Reduced Propionibacterium | Al-Ghazzewi and Tester, 2010 | |||||
Molecular weight 1000–6000 Da | Microculture with human faeces | Selective stimulation of beneficial gut microbiota and a favourable SCFA profile | Connolly et al., 2010 | |||
Containing less than 10% by weight degree of DP 3 | Single microculture | Enhanced lactic acid bacteria | Al-Ghazzewi and Tester, 2012 | |||
Molecular weight 1000–6000 Da | Co-microculture | Reduced Staphylococcus aureus and Salmonella typhimurium | Al-Ghazzewi et al., 2012 | |||
2000 u, 5000 u, 10000 u | Single microculture | Enhanced the proliferation of Lactobacillus acidophilus | Wang et al., 2015 | |||
DP 2–6 | Single microculture | Enhanced four different lactic acid bacteria | Wang et al., 2016b | |||
Co-microculture | Lactobacillus plantarum was the dominant strain in the co-culture with Enterococcus | Guo et al., 2017 | ||||
Microculture with human faeces | Improved the composition of fermentation broth and the prebiotic effect can be enhanced by γ-irradiation | Li et al., 2017 | ||||
| ||||||
In vivo | Mice | Enhanced anaerobes and Lactobacillus; reduced Clostridium perfringens and Escherichia coli | Elamir et al., 2008 | |||
Female patients suffering from vaginal infection | Decreased the clue cells and yeast-like fungi | Tester et al., 2012 | ||||
Female patients suffering from acne vulgaris | Improved skin health | Bateni et al., 2013 | ||||
Molecular weight <10 000 Da and >10 000 Da | Patients suffering IBD | Improve the patients’ life style | Suwannaporn et al., 2013 | |||
DP 2–10 | Mice | Enhanced Bifidobacterium and Lactobacillus | Qin et al., 2014 | |||
DP 2–10 ≥85%, DP 2–6 ≥50% | Ulcerative colitis mice | Decreased the ulcer areas and rates of the colon | Feng et al., 2015 | |||
DP 2–4 | Mice | Improved the gut environment; enhanced the probiotics | Wan et al., 2015 | |||
DP 2–4 | Rat | Improved the intestinal environment; regular intestinal flora | Wang et al., 2016a | |||
DP 2–10 ≥85%, DP 2–6≥50% | Ulcerative colitis rat | Improved the gut environment; improved the gut microbiota structure; anti-inflammatory | Liu et al., 2016 | |||
DP 2–10 ≥85% | Ulcerative colitis rat | Improved the gut environment; improved the gut microbiota structure | Liu et al., 2017 |
DP: degree of polymerization; IBD: inflammatory bowel disease; SCFA: short chain fatty acid